MDS Beacon articles – for the latest research and trial updates

The MDS Beacon is a great source of information on MDS.

There you can find the latest research articles – in a language patients can understand.
We used some of their articles in our latest newsletter – but if you’d like to read more, do check their website online:

For example:

Campath May Be Effective In Some Patients With Lower-Risk Myelodysplastic Syndromes

A small retrospective study by German researchers suggests that a short course of treatment with the im­mu­no­sup­pres­sive agent Campath may be safe and ef­fec­tive in patients with lower-risk myelo­dys­plastic syndromes who are good can­di­dates for im­mu­no­sup­pres­sive therapy.
More on

Half Of MDS Patients With Chromosome 5 Deletion Also Have Important Genetic Mutations

European researchers recently published results of a study looking at genetic mutations in myelodysplastic syndromes patients with a deletion in chromosome 5.

In their study, the researchers focused on 25 genes that often are mutated in patients with myeloid disorders, which include myelodysplastic syn­dromes (MDS), acute myeloid leukemia, and several other diseases.
More on

Zolinza Plus Cytarabine May Be A Good Treatment Option For Higher-Risk MDS Patients Following Vidaza Treatment Failure

Results of a recent Phase 1 clinical trial conducted in France show that treat­ment with Zolinza and low-dose cytarabine is safe and possibly more effective than current treat­ment options for higher-risk MDS patients who no longer respond to Vidaza treat­ment.
More on

Do check in regularly.

Free donations by shopping